Toxicity Assessment of Pelvic Intensity-Modulated Radiotherapy With Hypofractionated Simultaneous Integrated Boost to Prostate for Intermediate- and High-Risk Prostate Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 75, Issue 2, 2009, Pages 413-420

  McCammon, Robert ^a   Rusthoven, Kyle E ^a   Kavanagh, Brian ^a   Newell, Sherri ^a   Newman, Francis ^a   Raben, David ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

IMRT; Intensity modulated radiotherapy; Pelvic; Prostate cancer; Simultaneous integrated boost

Indexed keywords

IMRT; INTENSITY-MODULATED RADIOTHERAPY; PELVIC; PROSTATE CANCER; SIMULTANEOUS INTEGRATED BOOST;

PATIENT MONITORING; PHYSICAL THERAPY; RADIOTHERAPY; TERMINOLOGY;

TOXICITY;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BLADDER SPASM; BLEEDING; CANCER CENTER; CLINICAL ARTICLE; COLITIS; CONTROLLED STUDY; CYSTITIS; DIARRHEA; FECES INCONTINENCE; FEMALE; FOLLOW UP; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROCTITIS; PROSTATE CANCER; RADIATION DOSE; SCORING SYSTEM; URINARY FREQUENCY; URINARY URGENCY;

AGED; ANDROGEN ANTAGONISTS; CYSTITIS; DOSE FRACTIONATION; HUMANS; INTESTINES; LYMPHATIC IRRADIATION; MALE; MIDDLE AGED; PELVIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES; URINARY BLADDER; URINATION DISORDERS;

EID: 69549126349     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.10.050     Document Type: Article

References (39)

1. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: Results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002) 1097-1105
2. Kuban D.A., Tucker S.L., Dong L., et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70 (2008) 67-74
3. Dearnaley D.P., Hall E., Lawrence D., et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer 92 (2005) 488-498
4. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 294 (2005) 1233-1239
5. Roach III M., DeSilvio M.L., Lawton C., et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21 (2003) 1904-1911
6. Lawton C., DeSilvio M.L., Roach III M., et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 69 (2007) 646-655
7. Pommier P., Chabaud S., Lagrange J.L., et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 25 (2007) 5366-5367
8. Roach III M., Bae K., Speight J., et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610. J Clin Oncol 26 (2008) 585-589
9. Pilepich M.V., Winter K., Lawton C., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-Long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61 (2005) 1285-1290
10. Hanks G.E., Pajak T.F., Porter A., et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group protocol 92-02. J Clin Oncol 21 (2003) 3972-3978
11. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 360 (2002) 103-106
12. D'Amico A.V., Manola J., Loffredo M., et al. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 292 (2004) 821-827
13. Denham J.W., Steigler A., Lamb D.S., et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 6 (2005) 841-850
14. Brenner D.J., and Hall E.J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43 (1999) 1095-1101
15. Bentzen S.M., and Ritter M.A. The α/β ratio for prostate cancer: What is it, really?. Radiother Oncol 76 (2005) 1-3
16. King C.R., and Fowler J.F. A simple analytic derivation suggests that prostate cancer alpha/beta ratio is low. Int J Radiat Oncol Biol Phys 51 (2001) 213-214
17. Brenner D.J., Martinez A.A., Edmundson G.K., et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52 (2002) 6-13
18. Fowler J., Chappell R., and Ritter M. Is alpha/beta for prostate tumors really low?. Int J Radiat Oncol Biol Phys 50 (2001) 1021-1031
19. Brenner D.J. Fractionation and late rectal toxicity. Int J Radiat Oncol Biol Phys 60 (2004) 1013-1015
20. Deore S.M., Shrivastava S.K., Supe S.J., et al. Alpha/beta value and importance of dose per fraction for the late rectal and recto-sigmoid complications. Strahlenther Onkol 169 (1993) 521-526
21. Kupelian P.A., Willoughby T.R., Reddy C.A., et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 68 (2007) 1424-1430
22. Yeoh E.E., Holloway R.H., Fraser R.H., et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: Updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys 66 (2006) 1072-1083
23. Lukka H., Hayter C., Julian J.A., et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 23 (2005) 6132-6138
24. Hong T.S., Tome W.A., Jaradat H., et al. Pelvic nodal dose escalation with prostate hypofractionation using conformal avoidance defined (H-CAD) intensity modulated radiation therapy. Acta Oncol 45 (2006) 717-727
25. Madsen B.L., His R.A., Pham H.T., et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial results. Int J Radiat Oncol Biol Phys 67 (2007) 1099-1105
26. Soete G., Arcangeli S., De Meerleer G., et al. Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: Report on acute toxicity. Radiother Oncol 80 (2006) 78-81
27. D'Amico A.V., Chen M.H., Renshaw A.A., et al. Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial. JAMA 299 (2008) 289-295
28. Sebag-Montfiore D., Quirke P., Steele R., et al. The impact of short course pre-operative radiotherapy on patients' quality of life: Data from the MRC CR07/NCIC CO16 randomised clinical trial in patients with rectal cancer. Int J Radiat Oncol Biol Phys 72 (2008) S61
29. RTOG protocols 0418, 0529 and 0822. Radiation Therapy Oncology Group Website. Available from: www.rtog.org. Accessed September 27, 2008.
30. Li X.A., Wang J.Z., Jursinic P.A., et al. Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 61 (2005) 1251-1257
31. Roach M., Marquez C., You H., et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 28 (1993) 33-37
32. Nutting C.M., Convery D.J., Cosgrove V.P., et al. Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. Int J Radiat Oncol Biol Phys 48 (2000) 649-656
33. Ashman J.B., Zelefsky M.J., Hunt M.S., et al. Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 63 (2005) 765-771
34. Zelefsky M.J., Fuks Z., Hunt M., et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166 (2001) 876-881
35. Luxton G., Hancock S.L., and Boyer A.L. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys 59 (2004) 267-284
36. Guckenberger M., Baier K., Richter A., et al. Does intensity modulated radiation therapy (IMRT) prevent additional toxicity of treating the pelvic lymph nodes compared to treatment of the prostate only?. Radiat Oncol 3 (2008) 3
37. Pollack A., Hanlon A.L., Horowitz E.M., et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 64 (2006) 518-526
38. Lim T.S., Cheung P.C., Loblaw D.A., et al. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: Acute toxicity results. Int J Radiat Oncol Biol Phys 72 (2008) 85-92
39. Arcangeli S., Saracino B., Petrongari M.G., et al. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area. Radiother Oncol 84 (2007) 148-155